Directly or indirectly, cancer will touch everyone's lives. There is no greater or more worthwhile challenge than the ongoing battle to develop and improve anti-cancer treatments, for everyone's sake.
 |
programme of research
University of Bradford
2001/2
YCR Laboratory of Drug Design
The Tom Connors Cancer Research Centre
Director: Professor T.C. Jenkins
T.C. Jenkins
S.L. Moores
NQO2 enzyme-directed strategies for use in ENACT therapy
T.C. Jenkins
L.J. Adams
J.R.P. Arnold
T. Brown
G. Wilkinson
Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) as DNA-targeting agents
T.C. Jenkins
J.R.P. Arnold
P.J. Perry
T.A. Norris
T. Brown
DNA tetraplex-binding ligands as novel inhibitors of telomerase
P.J. Perry
J.R.P. Arnold
T.C. Jenkins
Activation of p53 response through inhibition of the p53-MDM2 complex
T.C. Jenkins
P.J. Perry
Mutagenic profiling of DNA-interactive anti-cancer drugs
P.J. Perry
T.A. Norris
T.C. Jenkins
Microtubule inhibitors: chalcones as mimics of combretastatin A-4
P.J. Perry
J.R.P. Arnold
T.C. Jenkins
CYP1B1-activated prodrugs in novel anti-cancer therapies
T.C. Jenkins
J.R.P. Arnold
T.A. Norris
P.J. Perry
Novel mRNA-targeted therapeutic agents
J.R.P. Arnold
T.C. Jenkins
Interactions of thymidylate synthase with RNA and clinical anti-tumour agents
J.R.P. Arnold
Antisense nucleic acid systems for therapeutic control
T.C. Jenkins
J.R.P. Arnold
Studies of nucleic acid structure and thermodynamics
J.R.P. Arnold
Development of ribozyme-based anti-cancer therapy
|